Cisapride (DrugBank: Cisapride)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis/Neuromyelitis optica | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2010-023996-25-BE (EUCTR) | 21/12/2010 | 25/11/2010 | The effect of fluoxetine and 5-HT4 serotonin receptor agonists on cerebral axonal energy metabolism and glutamate levels in multiple sclerosis. | The effect of fluoxetine and 5-HT4 serotonin receptor agonists on cerebral axonal energy metabolism and glutamate levels in multiple sclerosis. | Multiple sclerosis (both relapsing remitting and progressive forms) | Product Name: fluoxetine Other descriptive name: FLUOXETINE Product Name: Cisapride INN or Proposed INN: CISAPRIDE Product Name: Prucalopride INN or Proposed INN: PRUCALOPRIDE | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 32 | Belgium |